Dr. Richards on Unanswered Questions in Treating Bladder Cancer

Kyle A. Richards, MD
Published: Tuesday, Nov 03, 2015



Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

There have not been major advancements in bladder cancer over the last few decades: survival has remained stagnant and there continues to be a lack of approved therapies. Therefore, there are several areas of improvement in the field of bladder cancer, Richards explains.

For the future, Richard envisions more targeted therapies being available for patients. There is promising data from the Cancer Genome Atlas, which shows that researchers can individualize each patient’s bladder cancer and tailor treatments to those patients.

SELECTED
LANGUAGE


Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

There have not been major advancements in bladder cancer over the last few decades: survival has remained stagnant and there continues to be a lack of approved therapies. Therefore, there are several areas of improvement in the field of bladder cancer, Richards explains.

For the future, Richard envisions more targeted therapies being available for patients. There is promising data from the Cancer Genome Atlas, which shows that researchers can individualize each patient’s bladder cancer and tailor treatments to those patients.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x